Exelixis, Inc.
Exelixis, Inc. (EXEL) is a clinical-stage biotechnology company focused on developing and commercialising oncology therapies. Its best-known product is cabozantinib, approved for several cancer indications and a core revenue driver, while Exelixis pursues additional indications and combination studies to expand clinical use. The company operates a mix of internal development and partnering arrangements to fund research and broaden geographic reach. Investors should note the typical biotech profile: potential for significant upside from successful trials and approvals, balanced by regulatory, clinical and competitive risks that can materially affect valuation. Financial performance can be volatile and is often linked to milestone payments, royalties and product sales. With a market capitalisation near $9.7 billion, Exelixis is a meaningful mid‑cap biotech but remains exposed to trial outcomes, patent timelines and pricing pressures. This information is educational, not personal investment advice; suitability depends on individual circumstances and investments can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Exelixis' stock with a target price of $34.32, indicating potential growth.
Financial Health
Exelixis, Inc. is producing strong revenue and profits, with healthy cash flow and margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EXEL
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Ongoing trials and potential label expansions could drive re‑rating, though outcomes are uncertain and can move the share price sharply.
Core drug focus
Cabozantinib is central to revenue and pipeline strategy; success in new indications could extend commercial life but competition is strong.
Partnership reach
Collaborations and licensing deals help fund development and broaden market access, though partner terms and regional reimbursement affect returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
